Patent · US Active

Recombinant constructs and their use in reducing gene expression

US7897383B2 · kind B2 · utility

0Cited by

12References

2Claims

0Family size

Assignees

E.I. DU PONT DE NEMOURS AND COMPANY · US
PIONEER HI-BRED INTERNATIONAL, INC. · US

Inventors

Anthony J. Kinney · Wilmington, US
Kimberly F. Glassman · Maple Grove, US
William J. Gordon-Kamm · Urbandale, US
Keith Lowe · Johnston, US
Scott E. Nichols · Irwin, US
Kevin L. Stecca · Grimes, US

Key dates

Filing date	Oct 23, 2008
Grant date	Mar 1, 2011
Priority date	—
Expiry date	Mar 28, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/8251
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Recombinant constructs useful for reducing the expression of endogenous mRNA and any substantially similar endogenous mRNA are disclosed. In particular, a recombinant construct comprising, inter alia, a suitable nucleic acid sequence and its reverse complement can be used to alter the expression of any homologous, endogenous RNA (i.e., the target RNA) which is in proximity to this suitable nucleic acid sequence.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.